Mr. Albright has been an operating executive in several health care industry sectors and active in the health care private equity community for nearly two decades. He served as CEO of Gentiae Clinical Research, Free & Clear, Inc., and interim CEO of NVision, Inc. He was previously a senior executive at several other high growth health care companies, including Datis Corporation, and Vivra Specialty Partners, where he managed the site management and clinical research businesses.
In addition to WCCT Global, LLC, Mr. Albright currently serves on the Board of Directors for U.S. HealthWorks, Inc. Until its sale to Inverness Medical/Alere in September 2009, Mr. Albright served on the Board of Directors of Free & Clear, Inc. He also serves in a voluntary capacity as an advisor to UCSF and Mission Bay Capital, its internal incubator fund.
Mr. Albright graduated from Stanford with a BA in Economics, with Honors, and subsequently graduated from the Stanford Graduate School of Business where he received his MBA.
Mr. Cho currently resides in Hong Kong and serves as a Director in Citigroup’s Global Healthcare Investment Banking team where he is responsible for healthcare client coverage across the Asia Pacific region focused on China, South Korea, and Southeast Asia. He has nearly 15 years of professional experience exclusively in healthcare including ten years in investment banking based in New York and Hong Kong. Mr. Cho has facilitated numerous strategic and capital markets transactions on behalf of many global and regional healthcare companies based in the United States and across the Asia Pacific. He has spoken at numerous healthcare conferences covering a variety of topics ranging from biopharma innovation to M&A / capital markets trends. Mr. Cho was previously with Comprehensive NeuroScience in strategy and operations, and Ernst & Young as an auditor focused on California-based healthcare companies.
Mr. Cho was born in Korea and raised in California, and received his BS from the University of Southern California, MS from the University of Virginia, and MBA from the Wharton School of University of Pennsylvania.
Mark G. Hilderbrand
Mr. Hilderbrand has been a Managing Director at Housatonic Partners since 2006 and has more than 16 years of experience in private equity. Prior to Housatonic, he was a General Partner at Onset Ventures and worked at Summit Partners, where he focused on recapitalizations and buyouts of high-growth technology and services businesses. Earlier in his career, he worked as a management consultant at Bain & Company.Mr. Hilderbrand holds a BS from Boston University, an MS from Stanford University, and an MBA from the Harvard Business School. He led the firm’s investment in Exponential Media and is a Director of Learner’s Digest International, LLC; Onrad, Inc; Onsite Heath, Inc; QMC International, LLC; WCCT Global, LLC; and the Harvard Business School Alumni Association of Northern California.
Kenneth T. Kim
Dr. Kenneth Kim, a summa cum laude graduate of Harvard College, received his MD from Harvard Medical School. Following a fellowship at the MIT Sloan School of Management, he completed his internal medicine and allergy/immunology training at UCLA. He is the founder and CEO of WCCT Global LLC, an early phase drug development clinical CRO, based in the United States with 180 beds in 2 locations. Dr. Kim has served as a medical monitor, consultant, or investigator on over 500 clinical trials, having published over 30 research articles and 50 abstracts in peer reviewed journals. He has presented to the FDA on challenges and strategies of dose selection and study design for pediatric trials and met key decision makers at the PMDA, SFDA, and KFDA. He has spoken at multiple national and international meetings and is a well recognized expert in the areas of clinical pharmacology, ethnobridging, and respiratory and allergic diseases.
Paul H. Kim
Mr. Kim has over 20 years of professional experience in R&D and business management in bio industry. He started his career at Genentech in 1994, a global leader in biotechnology. Before founding Medivate, Mr. Kim served as the Head of Novartis Venture Fund Korea (NVFK) – first global pharmaceutical fund to focus solely on innovative Korean biotech investments. Most recently Mr. Kim served as co-founder and head of POSCO BioVentures – $62M Venture Fund focused on US & EU biotech investments on behalf of POSCO, $40B steel conglomerate. Mr. Kim also served as the Vice President of Business Development at ViroMed (KOSDAQ: 084990), a leading public biotherapeutics company, overseeing the company’s corporate development activities. Prior to ViroMed, Mr. Kim served as Vice President at CrystalGenomics (KOSDAQ 083790), forging key strategic partnerships during his tenure. Mr. Kim received his bachelor’s degree in Molecular Cell Biology from U.C. Berkeley, and is a graduate of Life Sciences Executive program. Currently, Mr. Kim is a member of NVCA (National Venture Capital Association) and Bio chapter member of LESI (Licensing Executives Society International).
Bill Taaffe retired from ICON Clinical Research in June 2011 after 40 years’ experience within the pharmaceutical and CRO industry. He was one of the founding members of ICON where he held the position of President and Chief Executive Officer, North America . He was 18 years with ICON. Prior to that, Bill spent 2 years with a generic pharmaceutical company, Circa Pharmaceuticals, 2 years with a pre-clinical research organization, Bioresearch and 18 years with a global CRO, The Institute of Clinical Pharmacology where he served as Chief Executive Officer, USA . He holds a B.Sc. from University College Dublin, Ireland . Bill moved to the USA in 1984 and now lives in Brentwood, TN, a suburb of Nashville. He is married with 5 children and 7 grandchildren.